2017 Award Recipient: Michael N. Hall, Ph.D.
When?
Monday, May 1, 2017
6:00 pm
Where?
National Press Club
529 14th Street NW,
Washington, DC 20045
Professor of Biochemistry, Biozentrum of the University of Basel, Switzerland
The 2017 Selection Committee announced cell growth research pioneer Michael N. Hall will receive the 2017 Szent-Györgyi Prize for Progress in Cancer Research.
In 1991, Hall discovered one of the most important cancer cell targets in the modern era of oncology, which he named “Target of Rapamycin” or TOR. He discovered that TOR – a conserved protein kinase – controls cell growth and a wide range of metabolic processes that when dysregulated cause disorders such as cancers, cardiovascular disease, diabetes and obesity. TOR inhibitors are used today in treatments for kidney, breast, brain and pancreatic cancers, and numerous clinical trials are currently underway testing TOR inhibitors in the treatments of many types of cancer.
Featured Items
"NFCR helps us focus where focus is needed most. They convene the discussions we must be having, guiding the discoverers who are exploring uncharted ground. NFCR is the navigator."
- Ronald DePinho, M.D., former President of MD Anderson Cancer Center
Ron DePinho“The NFCR Global Summit is a different kind of meeting, which is what makes it so impactful. It's an immersive experience. It's where top global leaders, from all areas in cancer, all brainstorm together to develop next-level new approaches and form new partnerships. The spirit of this meeting is very uplifting.” -Drew Pardoll, MD, PhD, Johns Hopkins University
Drew Pardoll, MD, PhD"Our continuing studies to profile T cells recognizing virus-positive vs virus-negative MCCs will build on these initial findings to provide an in-depth characterization of the immune response against MCCs. We anticipate that such work may lead to enhanced therapeutics and immune monitoring tools. Please know how much NFCR funding is appreciated in support of these investigations."
- Dr. Suzanne Topalian, NFCR-Supported Scientist at Johns Hopkins University
Dr. Suzanne Topalian“If we are going to succeed at this “moonshot” goal to rid the world of cancer, it will be an organization like NFCR leading the charge.”
- Joel, Loyal NFCR Supporter
Joel Snapshot ’25“Cancer is a beastly disease that brings misery to people. I believe in NFCR, and the science they support will help make a difference."
- Dorothy, Long-Time NFCR Supporter
Dorothy Snapshot ’25
